About Geron Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.geron.com/
Frequently Asked Questions
What is the 52-week range for GERN?
The 52-week high is $2.01 and the 52-week low is $1.04.
What is the P/E ratio for GERN?
The P/E ratio data is currently unavailable.
What is the dividend yield for GERN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -29.32%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -33.05%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.73.
Analyst Recommendation Trends
Wall Street analyst consensus for GERN over the last few months:
Latest GERN News
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective September 17, 2026, it granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS. Dur
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Spiegel Robert J. | +6,351 | $1.23 | $7,812 |
| 2026-06-30 | Spiegel Robert J. | +6,103 | $1.28 | $7,812 |
| 2026-05-20 | McDonald John F | +220,000 | - | - |
| 2026-05-20 | O'Farrell Elizabeth G. | +220,000 | - | - |
| 2026-05-20 | Bir Dawn Carter | +220,000 | - | - |
| 2026-05-20 | Molineaux Susan | +220,000 | - | - |
| 2026-05-20 | Spiegel Robert J. | +220,000 | - | - |
| 2026-04-13 | Williams Timothy | +2,500,000 | - | - |
| 2026-03-31 | Spiegel Robert J. | +5,243 | $1.49 | $7,812 |
| 2026-03-25 | Chinoporos Constantine | +270,000 | - | - |
| 2026-03-25 | Andrews Patricia S | +270,000 | - | - |
| 2026-02-18 | ROBERTSON MICHELLE | -27,500 | - | - |
| 2026-02-18 | ROBERTSON MICHELLE | -9,855 | $1.94 | $19,119 |
| 2026-02-18 | ROBERTSON MICHELLE | +27,500 | - | - |
| 2026-02-17 | Eid Joseph | +2,220,000 | - | - |
| 2026-02-17 | ROBERTSON MICHELLE | +1,660,000 | - | - |
| 2025-12-31 | Spiegel Robert J. | +5,918 | $1.32 | $7,812 |
| 2025-10-20 | ElNawawi Ahmed | +3,000,000 | - | - |